MK-2206 2HCl

目录号:S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl是一种高度选择性的Akt1/2/3抑制剂,在无细胞试验中IC50分别为8 nM/12 nM/65 nM;对250种其他蛋白激酶没有抑制活性。Phase 2。

规格 价格 库存 购买数量  
RMB 1789.01 现货
RMB 895.01 现货
RMB 1403.57 现货
RMB 3032.85 现货
RMB 4655.02 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献182篇:

客户使用该产品的21个实验数据:

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    j,k, Gene expression ofMYOCD (j) and ACTA2 ( SMA, k) after applying inhibitors of key components involved in the DDR2 downstream signalling pathway to HSCs cultured within 3D collagen matrix subjected to stretching (ST) (n=3, one-way ANOVA, **P=0.0036, ****P<0.0001). l,m, Expression of SMA was significantly reduced after treatment with related inhibitors in early-stage FμNs. (n=4, one-way ANOVA, ***P=0.001, ****P<0.0001). AKT-i: MK-2206

    Nature Materials, 2017, 16:1252-1261.. MK-2206 2HCl purchased from Selleck.

  • Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

    The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

  • Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

    VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

  • Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

    Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

  • IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

    Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

  • Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

    A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

  • Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    (B) Dose-response curves for DIPG 4 and SF7761 cells treated with the small molecule AKT inhibitor MK-2206 (error bars represent SEM).

    Oncol Rep, 2018, 39(2):455-464. MK-2206 2HCl purchased from Selleck.

  • C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

    Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

产品安全说明书

Akt抑制剂选择性比较

生物活性

产品描述 MK-2206 2HCl是一种高度选择性的Akt1/2/3抑制剂,在无细胞试验中IC50分别为8 nM/12 nM/65 nM;对250种其他蛋白激酶没有抑制活性。Phase 2。
特性 MK-2206是第一个进入临床研究阶段的Akt小分子变构抑制剂。
靶点
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
体外研究

MK-2206是变构抑制剂,由pleckstrin同源结构域激活。MK-2206抑制Akt的苏氨酸308位点和丝氨酸473位点的自身磷酸化作用。另外,MK-2206阻止Akt调节的下游信号分子(包括TSC2, PRAS40,及核糖体S6蛋白)的磷酸化作用。与抑制Ras 突变型细胞系(如NCI-H358, NCI-H23, NCI-H1299, 和Calu-6)相比,MK-2206 更有效地抑制Ras野生型细胞系(如A431, HCC827, 和NCI-H292)。MK-2206和细胞毒素药剂如erlotinib 和lapatinib联用作用于肺部NCI-H460肿瘤细胞或者卵巢A2780肿瘤细胞,MK-2206也显示出协同效应。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 NH3kOG1EgXSxdH;4bYMhSXO|YYm= Mk\0N{DPxE1? MofoO|IhcA>? M2nkfmROW09? M1fObWlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w NF3DbI8zODV5MUC2PS=>
A431 NIHyN5FMcW6jc3WgRZN{[Xl? Ml\4OUDPxE1? NHXIUIs2KGh? NGfuU|hFVVOR MmrUV5VxeHKnc4Pld{B1cGVic3nncoFtcW6pIH;mJGFsfCCjbnSgSZJs MmnxNlA2PzFyNkm=
HepG2 NVfiVZo6S3m2b4TvfIlkKEG|c3H5 NE\CU4gyOCEQvF2= NEHybJgzPCCq M1XONGROW09? M{LGSnNmdnOrdHn6[ZMhemW|aYP0ZY51KGOnbHzzJJRwKHSqZTDjfZRwfG:6aXOg[YZn\WO2IH;mJJNwemGoZX7pZi=> MXuyNVIxPTl{NR?=
Sk-Hep1 Mnn3R5l1d3SxeHnjJGF{e2G7 MYSxNEDPxE1? MnvqNlQhcA>? M4j1cGROW09? M33T[HNmdnOrdHn6[ZMhemW|aYP0ZY51KGOnbHzzJJRwKHSqZTDjfZRwfG:6aXOg[YZn\WO2IH;mJJNwemGoZX7pZi=> NXTUcoR7OjF{MEW5NlU>
OCUT1 cells harbored PIK3CA (H1047R+/+) MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvvT5o4OyEQvF2= MnPROUBl NYHqNnJiTE2VTx?= NFq3fIRKSzVyPUCuNVQh|ryP NGHiZYgzOTJ6OUK2Oy=>
K1 cells harbored PIK3CA (E542K+/+) MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DQc|Mh|ryP NXTCTXJEPSCm NY\iVVhETE2VTx?= MUXJR|UxRTBwNUKg{txO NVXmTIw2OjF{OEmyOlc>
FTC133 cells harbored PTEN (allele deletion and R130+) M1rJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[zbZpjOyEQvF2= MnL4OUBl NFOxTmVFVVOR MmHUTWM2OD1yLkG4JO69VQ>? NWnTdZp1OjF{OEmyOlc>
C643 cells harbored HRAS (G13R+/−) MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDzN{DPxE1? Mm\FOUBl M4rKbmROW09? NGfvO4xKSzVyPUCuNlch|ryP NFW3fG0zOTJ6OUK2Oy=>
Hth7 cells harbored NRAS (Q61R+/−) NUP6XJVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrEZpc{KM7:TR?= MXG1JIQ> NI[yTHFFVVOR MoHzTWM2OD12LkWg{txO NVL3bXk1OjF{OEmyOlc>
TPC1 cells harbored RET/PTC1 rearrangement Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXQWZc{KM7:TR?= M1j1dlUh\A>? NIexZmNFVVOR NYnNVWpkUUN3ME2wMlU6KM7:TR?= MmKzNlEzQDl{Nke=
Hth74 MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVL6V|FYOyEQvF2= NF7pVnA2KGR? M4npbmROW09? NUO5Vo5JUUN3ME2yMlE6KM7:TR?= NU\hNo1KOjF{OEmyOlc>
KAT18 M1TI[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HzNVMh|ryP MVK1JIQ> MYfEUXNQ NIPLenVKSzVyPUSuOlIh|ryP MmXyNlEzQDl{Nke=
SW1736 M2nKeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWSxNFAh|ryP NETKW4c2KGR? M3HySWROW09? MojXTWM2OD12Nz61OkDPxE1? M2PkW|IyOjh7Mk[3
WRO MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYCxNFAxKM7:TR?= MUC1JIQ> NVjI[mJqTE2VTx?= MlrkTWM2OD5zMECwJO69VQ>? MYeyNVI5QTJ4Nx?=
TAD2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH1NVAxOCEQvF2= M{WzV|Uh\A>? M3\3U2ROW09? NV\RcoJJUUN3ME6xNFAxKM7:TR?= NITleZQzOTJ6OUK2Oy=>
LN229 M1TqemFxd3C2b4Ppd{BCe3OjeR?= NWPwSnM5OC53IN88US=> M2XXXlYxKGh? MUHEUXNQ M4niWGF2\22nboTzJIFxd3C2b3flcolkKGWoZnXjeJMhd2ZiZ3XmbZRqdmmk Ml7FNlIxPTd7MUS=
T98G NH\JR3JCeG:ydH;zbZMhSXO|YYm= MUmwMlUh|ryP MmHGOlAhcA>? MoftSG1UVw>? MojHRZVodWWwdIOgZZBweHSxZ3XubYMh\W[oZXP0d{Bw\iCpZX\peIlvcWJ? NWDrVnZDOjJyNUe5NVQ>
HC11 NISz[5JHfW6ldHnvckBCe3OjeR?= MYexNEDPxE1? MV:yOEBp NWPGTXpCTE2VTx?= NV;vXmp[UW6qaXLpeJMh|rJvY3Hz[YlvKGGwZDDBSHJRKHO7boTo[ZNqew>? MlnqNlI1OjZ4MkG=
MOLT-4 M4\EZmN6fG:2b4jpZ{BCe3OjeR?= M4K5N|ExKM7:TR?= NEHVeWY1QCCq Mmr4SG1UVw>? NFTFdoNKSzVyPUGuO-KBkc7:TR?= MkPINlI3OTR{NEO=
CEM-R Mm\uR5l1d3SxeHnjJGF{e2G7 M4[2UVExKM7:TR?= MVS0PEBp M2jhOGROW09? MnTJTWM2OD1|LkRihKnPxE1? MX:yNlYyPDJ2Mx?=
CEM-S NH;VR3NEgXSxdH;4bYMhSXO|YYm= NWnSfGNvOTBizszN NFzKe2o1QCCq NFvrcHlFVVOR NGjMR|VKSzVyPUWuNgKBkc7:TR?= NELGNY8zOjZzNEK0Ny=>
MOLT-4 NGPuTIVHfW6ldHnvckBCe3OjeR?= M1HKeVExKM7:TR?= NXfXb4FNOjRiaB?= Mo\LSG1UVw>? M4exNWJtd2OtczDj[YxteyCrbjD0bIUhTzBxR{GgdIhie2Vib3[geIhmKGOnbHygZ5lkdGV? MUGyNlYyPDJ2Mx?=
MOLT-4 MUXGeY5kfGmxbjDBd5NigQ>? NH24b4k16oDLzszN MnKzOEBp MWPEUXNQ NEXSUlZKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDN2EwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ? NGfSNGwzOjZzNEK0Ny=>
CEM-R NVriXFAyTnWwY4Tpc44hSXO|YYm= NEDaWWM16oDLzszN MnfyOEBp NXTWRmJ6TE2VTx?= NGTkVnBKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDOGEwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ? NFzpc3MzOjZzNEK0Ny=>
CEM-S MnrZSpVv[3Srb36gRZN{[Xl? MmW0OQKBkc7:TR?= NFHMUJo1KGh? MVPEUXNQ MXfJcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFNVGvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI> NFHPfHQzOjZzNEK0Ny=>
HepG2 cell MUXLbY5ie2ViQYPzZZk> MUOyNEDPxE1? MXyyOEBp Mmm2SG1UVw>? MofXSI94dnKnZ4XsZZRmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? Mn;YNlM4QTd|MUm=
HepG2 cell NYrKXHp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:zNEDPxE1? NWK2dI5FOjRiaB?= M2HPcmROW09? NHva[oNKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NUPReIMyOjN5OUezNVk>
HepG2 cell MVvBdI9xfG:|aYOgRZN{[Xl? MUWyNEDPxE1? M3LaTFI1KGh? M17IZ2ROW09? MoDsTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M{m1TFI{Pzl5M{G5
GEO NF3PdpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmewOVAxKG6P NV3GPW1YPzJiaB?= NWO4TGVLTE2VTx?= Ml\HTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NXjSVGs{OjR3OEGyN|E>
CNE-1 NX7tXXo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqxNEDPxE1? NFXwZ5U6PiCq Mo\qSG1UVw>? MnzMTWM2OD1{Lkm2JO69VQ>? MW[yOVM{Pjl{NR?=
CNE-2 M372NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmxNEDPxE1? MVi5OkBp NESzfYVFVVOR NH\m[nNKSzVyPUSuOVMh|ryP NGDRSHgzPTN|NkmyOS=>
HONE-1 MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHWy[48yOCEQvF2= NWnlVIoxQTZiaB?= NUjRcYxRTE2VTx?= NHHzc3FKSzVyPUOuN|ch|ryP M3L0VVI2OzN4OUK1
SUNE-1 NV3mfGg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;OcJRtOTBizszN MlL1PVYhcA>? MXTEUXNQ MVjJR|UxRTBwNUKg{txO NHfCWnYzPTN|NkmyOS=>
CNE-2 NHTVXopHfW6ldHnvckBCe3OjeR?= MVexNEDPxE1? MkHTOFghcA>? M2rNcGROW09? NYL3T3ZTUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCJMR?= NHv4eFUzPTN|NkmyOS=>
HONE-1 MojySpVv[3Srb36gRZN{[Xl? MV6xNEDPxE1? M2j4XVQ5KGh? NH7uWZJFVVOR NFHJUIlKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KEdz MWiyOVM{Pjl{NR?=
NEC8 NH3oTpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHnZmVKSzVyPUCuNFk3PTFizszN MkT2V2FPT0WU
P12-ICHIKAWA MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMUG2NkDPxE1? MVfTRW5ITVJ?
MDA-MB-175-VII M4Oxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfVdphKSzVyPUCuNVM4OzhizszN NV;reVJrW0GQR1XS
AsPC-1 NGPwRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M130OGlEPTB;MD6yNlEzOiEQvF2= NYfJO4tlW0GQR1XS
T47D MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nMRmlEPTB;MD6yPFI2KM7:TR?= M4K4XnNCVkeHUh?=
HH M1XWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTSRXNnUUN3ME2wMlMxOjh|IN88US=> NFT1TWtUSU6JRWK=
MOLT-16 NYLDfFZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTlTWM2OD1yLkOwN|Ih|ryP NYXYUJhsW0GQR1XS
ES5 MmjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnHWlBKSzVyPUCuN|Q1PTVizszN NFfE[WFUSU6JRWK=
RS4-11 MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1e2T2lEPTB;MD6zOFYyKM7:TR?= NVvFbYFkW0GQR1XS
KARPAS-45 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrue4tKSzVyPUCuN|c{OjFizszN NVTW[4ZZW0GQR1XS
NCI-H720 M37KfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly0TWM2OD1yLkO3Olc6KM7:TR?= NFvWbWJUSU6JRWK=
H9 M3XTOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIezfW5KSzVyPUCuN|g5QDNizszN NV;HS4NyW0GQR1XS
EFM-19 MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zhXWlEPTB;MD60OFAyKM7:TR?= MlO3V2FPT0WU
SBC-1 MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfmWFRKSzVyPUCuOFQxOzVizszN NHSzXoNUSU6JRWK=
A4-Fuk M4DZc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLrVY1KSzVyPUCuOFY5PjhizszN NET0b49USU6JRWK=
NCI-H1563 Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILQelVKSzVyPUCuOFgyQDlizszN Mn72V2FPT0WU
HCC1419 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XWOmlEPTB;MD60PFg6OiEQvF2= MWDTRW5ITVJ?
H-EMC-SS M2LvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfHWlBKSzVyPUCuOFk6OzlizszN NGHy[IxUSU6JRWK=
BHT-101 NVvHVG5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\UfVNKSzVyPUCuOVI6PjFizszN NUPyOHJUW0GQR1XS
IGROV-1 NIf1OVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HqN2lEPTB;MD61OVI1QSEQvF2= NUm4XnJYW0GQR1XS
HGC-27 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDIVnRKSzVyPUCuOVY4QDNizszN NFLJ[JVUSU6JRWK=
MDA-MB-361 NISwPGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\TUoh2UUN3ME2wMlU4PzZzIN88US=> Mn;NV2FPT0WU
KE-37 NHvVO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jVUmlEPTB;MD61PFI3KM7:TR?= NFHldXNUSU6JRWK=
HCC70 MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwNUm4Nlch|ryP MkLYV2FPT0WU
LNCaP-Clone-FGC MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\FTWM2OD1yLk[xNFQ5KM7:TR?= M1GwTnNCVkeHUh?=
HAL-01 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwNkKxN{DPxE1? NEO3Ro1USU6JRWK=
HT MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIO4bmVKSzVyPUCuOlMzOzlizszN M1[3SnNCVkeHUh?=
MDA-MB-415 MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlezTWM2OD1yLk[zOlI3KM7:TR?= M4T6cnNCVkeHUh?=
NOS-1 MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwNkO3NlMh|ryP NWqwTmlFW0GQR1XS
DU-145 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr0[WJKSzVyPUCuOlQ4PDVizszN NIPDV4RUSU6JRWK=
OCUB-M MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWSzeYdyUUN3ME2wMlcxQTZ4IN88US=> NEj4Wm5USU6JRWK=
VA-ES-BJ NVe2N4UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjzTWM2OD1yLkezNFI2KM7:TR?= NWHlSYxZW0GQR1XS
J-RT3-T3-5 MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnSUJpLUUN3ME2wMlc1PDB|IN88US=> M12zZ3NCVkeHUh?=
MOLT-4 M1[5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXubJBKSzVyPUCuPFA2QDJizszN M2DZVnNCVkeHUh?=
NB7 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvrTWM2OD1yLkiyOFEyKM7:TR?= NH:5T|dUSU6JRWK=
L-363 NX30VndzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jrUmlEPTB;MD64N|Q1OiEQvF2= MnLUV2FPT0WU
NKM-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHiwTHlKSzVyPUCuPFYzPTNizszN MlzJV2FPT0WU
HOP-92 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\OTWM2OD1yLki3NlI{KM7:TR?= MWDTRW5ITVJ?
OAW-42 M3v0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nWTGlEPTB;MD64PFczKM7:TR?= M{TQb3NCVkeHUh?=
HuO9 NFn5PFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjk[pJKSzVyPUCuPVI4PTFizszN MX7TRW5ITVJ?
MFE-280 MnTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwOU[0OlUh|ryP M2TzWHNCVkeHUh?=
EM-2 MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULMZ3NCUUN3ME2wMlk4QTN7IN88US=> NUH4W2hXW0GQR1XS
NCI-H520 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn6TWM2OD1yLkm4OVkzKM7:TR?= MV\TRW5ITVJ?
LB2241-RCC M3v2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme0TWM2OD1yLkm5O|M1KM7:TR?= MXjTRW5ITVJ?
SK-NEP-1 M4fsOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;QTWM2OD1zLkG0OFg2KM7:TR?= M2XrW3NCVkeHUh?=
LXF-289 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLLeo9KSzVyPUGuNVcyPTZizszN MljyV2FPT0WU
EPLC-272H MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzS[YlKSzVyPUGuNVczPTZizszN NUDXWlN4W0GQR1XS
COLO-684 NWeyOm95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjQdZllUUN3ME2xMlI{PzJ3IN88US=> MWfTRW5ITVJ?
ES1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfiO5pKSzVyPUGuNlQxPjVizszN M{HYOHNCVkeHUh?=
DOHH-2 MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHntUo5KSzVyPUGuNlgzODNizszN NUjhemJzW0GQR1XS
CTB-1 MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzleVhFUUN3ME2xMlI5QTlizszN M{jrenNCVkeHUh?=
G-401 Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u5[mlEPTB;MT6yPVc6PSEQvF2= NHTxWoNUSU6JRWK=
LoVo Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DjXGlEPTB;MT6zNlU{PCEQvF2= NFLFcVlUSU6JRWK=
Ramos-2G6-4C10 M1LHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPrTWM2OD1zLkOzO|AyKM7:TR?= NXXVNXYxW0GQR1XS
MFM-223 M3LhWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jrc2lEPTB;MT6zOFQ3OSEQvF2= M3PTZXNCVkeHUh?=
PA-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P0OmlEPTB;MT6zOVI3PSEQvF2= NWDvRpBxW0GQR1XS
697 NVXqWGFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTFwM{e2NVYh|ryP M2XM[XNCVkeHUh?=
QIMR-WIL M1XteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rKXmlEPTB;MT60PVEyPiEQvF2= MoG2V2FPT0WU
HOS NYewRolWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\rU|FKSzVyPUGuOFk2PThizszN NF7kT3JUSU6JRWK=
DMS-273 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjGTWM2OD1zLkWxPVU6KM7:TR?= NIrFbVlUSU6JRWK=
ME-180 NIDVTolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfTSYlKSzVyPUGuOVY5QTFizszN MlvEV2FPT0WU
HCC2218 M3PLTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljwTWM2OD1zLk[4NlI2KM7:TR?= M4i0cXNCVkeHUh?=
CAL-54 Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LjPGlEPTB;MT63NVI1OiEQvF2= MXTTRW5ITVJ?
OMC-1 NEjNSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFwN{S2O|ch|ryP M3KyXHNCVkeHUh?=
COR-L105 M1zydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTPfJdXUUN3ME2xMlc6PzN5IN88US=> MmjlV2FPT0WU
BV-173 MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;Cc2hvUUN3ME2xMlgyODd2IN88US=> MV7TRW5ITVJ?
RKO NFfjSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjrO4lqUUN3ME2xMlg4OTBzIN88US=> MnTUV2FPT0WU
SNU-387 NV;OfotJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3xTWM2OD1zLki4OFA3KM7:TR?= MYDTRW5ITVJ?
SW1088 M1;yN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjveol6UUN3ME2xMlk1PjB4IN88US=> M3uyT3NCVkeHUh?=
Hs-578-T NEPyXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHJNGtyUUN3ME2yMlEyPDN|IN88US=> MoPTV2FPT0WU
OC-314 NFrvXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nTWWlEPTB;Mj6xOVA5PiEQvF2= Mmi4V2FPT0WU
RMG-I Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G5d2lEPTB;Mj6xOlM6QCEQvF2= NX7ZZlI4W0GQR1XS
NCI-H1395 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXSbWhxUUN3ME2yMlE5ODlzIN88US=> NF3SVZdUSU6JRWK=
GAMG MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInjU41KSzVyPUKuNlM5PDVizszN NEXRc2JUSU6JRWK=
LB1047-RCC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTJwMkSzNVch|ryP MVPTRW5ITVJ?
MN-60 MkTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Txb2lEPTB;Mj6yPVkzOyEQvF2= M3rMUnNCVkeHUh?=
OAW-28 M3:xd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml64TWM2OD1{LkK5PVUyKM7:TR?= M1XGW3NCVkeHUh?=
NCI-H2228 MlL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDpTWM2OD1{LkOxOVUzKM7:TR?= NFuwOFFUSU6JRWK=
ABC-1 MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvXTWM2OD1{LkOzNlU{KM7:TR?= NGfnenBUSU6JRWK=
LS-513 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJwM{O0PFQh|ryP MmfLV2FPT0WU
KS-1 M1v5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfwTWM2OD1{LkO4NVkyKM7:TR?= NE\kRlRUSU6JRWK=
NB69 MkfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH2VZlKSzVyPUKuN|g6QDNizszN M4\F[nNCVkeHUh?=
VM-CUB-1 M135dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJwM{mwPFMh|ryP NV3pfJYxW0GQR1XS
D-423MG M32yWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFH1e3lKSzVyPUKuOFExPDRizszN MV\TRW5ITVJ?
EW-18 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3wb246UUN3ME2yMlQyQTN7IN88US=> M2[zNHNCVkeHUh?=
YH-13 NW\meottT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\UfWlEPTB;Mj60OlE2OyEQvF2= MmXHV2FPT0WU
T-24 NWjIUmJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3meZV4UUN3ME2yMlQ4QDhzIN88US=> MVvTRW5ITVJ?
ES8 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVr6VG0yUUN3ME2yMlQ6Ojh5IN88US=> NXvj[HRnW0GQR1XS
ES3 MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJwNEm3OVkh|ryP MWDTRW5ITVJ?
RXF393 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTPTWM2OD1{Lk[wOFg4KM7:TR?= M3uzW3NCVkeHUh?=
RPMI-8226 MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoCyTWM2OD1{Lk[yPVU{KM7:TR?= MXHTRW5ITVJ?
AGS NULsbI1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJwN{KxN|ch|ryP NHPRRY9USU6JRWK=
HCC1395 NUX6TG1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfue5hKSzVyPUKuO|UyQDdizszN MVPTRW5ITVJ?
MV-4-11 NIfIbJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPjTWM2OD1{Lke1NlY3KM7:TR?= MX\TRW5ITVJ?
A204 NUDMfotlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJwOEO4O|Ih|ryP MkjvV2FPT0WU
MCF7 NYDvZXRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX2TWM2OD1{Lki2NVE4KM7:TR?= NYLiNYE5W0GQR1XS
SNU-423 NXz3cYxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3oZ3RKSzVyPUKuPFkzPDJizszN NVTldGxXW0GQR1XS
NCI-H1048 MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL3[FZmUUN3ME2yMlk3QDZ3IN88US=> NYXK[3VFW0GQR1XS
GR-ST MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NViwWmtWUUN3ME2zMlA1PjFzIN88US=> M{TnUXNCVkeHUh?=
EoL-1- M4C5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELRSYtKSzVyPUOuNFcxPThizszN Mk\CV2FPT0WU
HuH-7 M1HTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPoZXBKSzVyPUOuNFk1PjRizszN M2OycnNCVkeHUh?=
OS-RC-2 NULC[21VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor2TWM2OD1|LkGxNVkh|ryP MX7TRW5ITVJ?
EW-3 NU\Mb41jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv4TWM2OD1|LkG5OVI6KM7:TR?= MWnTRW5ITVJ?
NCI-H747 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWC3NXpWUUN3ME2zMlIxPjl2IN88US=> NVLOSWJFW0GQR1XS
EW-16 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTNwMkG4O|kh|ryP Mn:0V2FPT0WU
DOK NH[zbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\nWoNvUUN3ME2zMlIzQDV7IN88US=> MoHnV2FPT0WU
HCC2157 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrjTWhKSzVyPUOuN|gyPzlizszN MlnYV2FPT0WU
OVCAR-3 NGjFXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTNwNEC3PFYh|ryP MVPTRW5ITVJ?
NCI-H1623 NVvWbXJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\xZWlEPTB;Mz60NVIzPCEQvF2= MYXTRW5ITVJ?
H4 M1vUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1G4cWlEPTB;Mz60OVYzPiEQvF2= Mnr2V2FPT0WU
SW1710 NVvwW5JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTNwNE[2O|gh|ryP NIDwSVNUSU6JRWK=
RT-112 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTNwNUKzPFgh|ryP M{T1c3NCVkeHUh?=
DMS-114 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7uVY9XUUN3ME2zMlYzOjd6IN88US=> M3rqPHNCVkeHUh?=
AN3-CA NUPtWI1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjJT3ZPUUN3ME2zMlYzPDV4IN88US=> M4jReHNCVkeHUh?=
KNS-62 MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFv3Rm9KSzVyPUOuOlM{OzhizszN M{XCZ3NCVkeHUh?=
SJRH30 MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;DeXdKSzVyPUOuOlkyOjJizszN NGfKSHdUSU6JRWK=
G-402 NIXGfnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYCxV2c2UUN3ME2zMlcxPzFzIN88US=> NFPoe5dUSU6JRWK=
MHH-PREB-1 NEHxNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL3SlFLUUN3ME2zMlczODN6IN88US=> M{mxbnNCVkeHUh?=
P30-OHK MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTNwOEC5O|Yh|ryP MnjHV2FPT0WU
RVH-421 NXjPVZQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP3W3ltUUN3ME2zMlgyPzh6IN88US=> NGTGWXJUSU6JRWK=
LU-134-A NWLB[2ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDRTWM2OD1|Lki4OFI5KM7:TR?= MV;TRW5ITVJ?
ECC10 NWj4bnJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTsTWM2OD1|LkmzOlIzKM7:TR?= MYPTRW5ITVJ?
TGW M4\ScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13VdmlEPTB;ND6wNlMxPSEQvF2= M2XzXnNCVkeHUh?=
MLMA M1P2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTRwMEK5OlYh|ryP MnzsV2FPT0WU
SCC-25 NVXFPItyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H0R2lEPTB;ND6wOlU3PiEQvF2= MlP0V2FPT0WU
TYK-nu M{XqNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTRwMEm1N|Qh|ryP MYXTRW5ITVJ?
LAMA-84 NVHVbm95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTRwMUSxPVEh|ryP MYTTRW5ITVJ?
Calu-3 NHL1UmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne2TWM2OD12LkK0OFE3KM7:TR?= MVXTRW5ITVJ?
NCI-H460 MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDqN21KSzVyPUSuNlY1PDNizszN M4jJcHNCVkeHUh?=
EGI-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXxUHZvUUN3ME20MlM4Pzd6IN88US=> MXnTRW5ITVJ?
NCI-H292 NH;1cXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXDVYhKSzVyPUSuN|gyPDZizszN NYDiU29VW0GQR1XS
HCE-T NVS5[nlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXLTWM2OD12LkSxOVc6KM7:TR?= MV;TRW5ITVJ?
EW-11 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{W3eWlEPTB;ND60NVg{QCEQvF2= NV7mZYJGW0GQR1XS
ATN-1 MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\HZo9CUUN3ME20MlQ1OzB2IN88US=> MoX0V2FPT0WU
NB5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DhN2lEPTB;ND61N|Y6PyEQvF2= M3mySXNCVkeHUh?=
KLE MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTRwN{CxPVgh|ryP MmK3V2FPT0WU
CAL-39 NVzHd2R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nqe2lEPTB;ND63NlE1PiEQvF2= MXLTRW5ITVJ?
TI-73 NGP4dotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTRwOEC2NFkh|ryP NYS4Z25tW0GQR1XS
HO-1-N-1 M4nxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO0XZhOUUN3ME20Mlk1OiEQvF2= NICzOWNUSU6JRWK=
786-0 NWjmSpBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXBbZNKSzVyPUSuPVQ3PzNizszN NIPpSYpUSU6JRWK=
SK-N-DZ NF:4dHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofkTWM2OD12Lkm2NVQzKM7:TR?= M1jMV3NCVkeHUh?=
NCI-H446 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojvTWM2OD13LkKwNFA6KM7:TR?= M3rzNXNCVkeHUh?=
ETK-1 MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH3TWM2OD13LkKxNVY2KM7:TR?= Ml\4V2FPT0WU
BT-20 Mn;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfP[4tKSzVyPUWuNlE{PTNizszN MmjsV2FPT0WU
MEL-HO NILiWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHldldbUUN3ME21MlM4OzN4IN88US=> M3XqPHNCVkeHUh?=
CAL-27 MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PDXGlEPTB;NT60OlM{QSEQvF2= M4fweHNCVkeHUh?=
SW872 Mkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDVTWM2OD13LkW5OFI5KM7:TR?= NF:xS4ZUSU6JRWK=
RPMI-2650 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;hRVBKSzVyPUWuOlYyQTlizszN MVPTRW5ITVJ?
PFSK-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTVwN{K3N|Ih|ryP MlT0V2FPT0WU
SF295 M2Xw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHGeGh5UUN3ME21MlgxPjN|IN88US=> NIi3Om5USU6JRWK=
Becker MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWewOpBHUUN3ME21Mlg3PDd{IN88US=> Mlj0V2FPT0WU
Saos-2 NUXPXnRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK3TWM2OD13Lki2OVMh|ryP NIS3SWVUSU6JRWK=
SK-OV-3 NX;wZZhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:wflhTUUN3ME21Mlk6QDF4IN88US=> NXzkTXE4W0GQR1XS
VMRC-RCZ M4PCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfBeplnUUN3ME22MlA5Pzd|IN88US=> MUXTRW5ITVJ?
EW-22 NIDOPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrOTJhKSzVyPU[uNVk3PDlizszN MofKV2FPT0WU
BT-474 NIDrN|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW4TWM2OD14LkKzN{DPxE1? MULTRW5ITVJ?
BFTC-909 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLmOWRKSzVyPU[uN|A{PDVizszN MXHTRW5ITVJ?
NB12 NGHPUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fpdmlEPTB;Nj6zPVA4OSEQvF2= M3n3O3NCVkeHUh?=
D-263MG MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTZwNEWxOlkh|ryP MYPTRW5ITVJ?
SNB75 M2LDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vaNWlEPTB;Nj62NFE1OyEQvF2= NHrncpRUSU6JRWK=
A704 M3nsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljqTWM2OD14Lk[zNFYh|ryP NV70[FBvW0GQR1XS
NCI-H1693 MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\aTWM2OD14Lk[zOlA1KM7:TR?= NHnld5hUSU6JRWK=
LN-405 NITYWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkG2TWM2OD14Lke5OlczKM7:TR?= NVPQVnE2W0GQR1XS
CHL-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\pW2lEPTB;Nj64NFA4QSEQvF2= M1TESXNCVkeHUh?=
A498 NXLCXXFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nVS2lEPTB;Nj64NVk3OSEQvF2= M3PYZ3NCVkeHUh?=
TE-12 NUPaeI5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTZwOEO4NVch|ryP MY\TRW5ITVJ?
TE-6 MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\KTWM2OD14LkmzNFM5KM7:TR?= M2jJbXNCVkeHUh?=
AU565 NIC3c5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17OSmlEPTB;Nj65Olk2PyEQvF2= NVXyc3VpW0GQR1XS
RD M2jFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXy4d4JxUUN3ME22Mlk5Ojh2IN88US=> NYL6SZFUW0GQR1XS
SW1463 M{C2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2H6fGlEPTB;Nz6xNVE3QCEQvF2= MkH1V2FPT0WU
LU-99A NEDoRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLWWIxKSzVyPUeuNVQ{OjJizszN MkX3V2FPT0WU
NCI-H28 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\ke3VKSzVyPUeuNlkzPCEQvF2= M3nRfnNCVkeHUh?=
MC-IXC NUXib2tFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnu3TWM2OD15LkS4OVc3KM7:TR?= MkjUV2FPT0WU
GP5d M{DkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHQdWhKSzVyPUeuOFg4PjRizszN MUjTRW5ITVJ?
GB-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIC5TpJKSzVyPUeuOVQ5ODRizszN NIHvS45USU6JRWK=
CAL-33 MkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInNPJVKSzVyPUeuOlYzOzNizszN NV71d5U3W0GQR1XS
MSTO-211H NHG5XlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfuTWM2OD15Lk[3N|M3KM7:TR?= MojsV2FPT0WU
TE-5 NWnSdXA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;zW4N7UUN3ME23Mlc6OzN2IN88US=> M{TjZXNCVkeHUh?=
D-566MG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[ydlZKSzVyPUiuNFQ1OjlizszN MWXTRW5ITVJ?
JVM-3 M1O0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXVTWM2OD16LkG1NlY5KM7:TR?= MWjTRW5ITVJ?
T98G NFnCcnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRThwMUiwOlch|ryP MofzV2FPT0WU
HCC1954 M4X5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3qzV2lEPTB;OD60OVExPCEQvF2= MnHrV2FPT0WU
SF126 Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRThwNEW5N|Yh|ryP M4LtUHNCVkeHUh?=
LB996-RCC MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDwTWM2OD16LkWzNlU4KM7:TR?= M1jB[XNCVkeHUh?=
SKG-IIIa MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfQ[WlKSzVyPUiuOlMxPjlizszN NX;KVHJLW0GQR1XS
NCI-SNU-1 NFnVTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHrTWM2OD16Lk[0OlQ{KM7:TR?= NYXjPVQyW0GQR1XS
LB771-HNC M1ryfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfRWWdIUUN3ME24MlY1Pjl4IN88US=> MVjTRW5ITVJ?
SCC-4 NV;oO3NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWK4clRyUUN3ME24MlY5OjF7IN88US=> MlLBV2FPT0WU
CAMA-1 NHL3bYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jaSmlEPTB;OD63O|E1PiEQvF2= MUDTRW5ITVJ?
D-502MG NXXZUIRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXWwd3hUUUN3ME24Mlc5PjJ7IN88US=> NUnIc4h2W0GQR1XS
ESS-1 M{PERWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRThwOEi3NFQh|ryP MV3TRW5ITVJ?
HEC-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[2NmlEPTB;OD64PVg3PiEQvF2= NIraZWtUSU6JRWK=
NB10 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLuTWM2OD17LkCyNlI1KM7:TR?= M4PweHNCVkeHUh?=
8505C MoPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rmPGlEPTB;OT6wOFI{OiEQvF2= MY\TRW5ITVJ?
EFO-27 NEHqdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHhUWJUUUN3ME25MlE3PDF{IN88US=> NVznVpVXW0GQR1XS
HN MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LwWmlEPTB;OT6xOlYzQCEQvF2= NHrQe2VUSU6JRWK=
DSH1 NE\IZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfuTWM2OD17LkKwPFch|ryP NVryTGI5W0GQR1XS
NBsusSR NYHRUXNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\ITWM2OD17LkK3OFAzKM7:TR?= NYTRO21CW0GQR1XS
LS-123 Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;i[GlEPTB;OT6zNVc3OSEQvF2= NF[2Nm9USU6JRWK=
SHP-77 NX\4fpNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTlwM{m5N|Uh|ryP M1HPNnNCVkeHUh?=
ACN NWLSc2FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF23NnJKSzVyPUmuOVMzPzdizszN NInWZXVUSU6JRWK=
U251 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHWXVgyUUN3ME25MlY2PTR2IN88US=> M1W1SXNCVkeHUh?=
A431 M1fRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTpNFd1UUN3ME25MlgxOjN6IN88US=> NH;Ydo9USU6JRWK=
5637 Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XT[mlEPTB;OT64OFk5PCEQvF2= M4K0fHNCVkeHUh?=
MDA-MB-157 NVGyfW97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3S2S2lEPTB;OT65Nlg4QCEQvF2= NXjj[Jc3W0GQR1XS
A101D M4PuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTlwOUm5O|Qh|ryP MYLTRW5ITVJ?
YKG-1 MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvaTWM2OD1zMD6yNFA3KM7:TR?= MnHPV2FPT0WU
LAN-6 MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{H1emlEPTB;MUCuNlE3PCEQvF2= NFK1S2NUSU6JRWK=
OVCAR-5 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLBbmRDUUN3ME2xNE4zPDN|IN88US=> NULMenhjW0GQR1XS
A549 MnvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37aV2lEPTB;MUCuN|k4OyEQvF2= NVLOdmVkW0GQR1XS
no-11 M1vYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO5b216UUN3ME2xNE41OzV|IN88US=> NWHTW4ltW0GQR1XS
SF539 MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTFyLkmwOFEh|ryP M{H0Z3NCVkeHUh?=
A388 NYmxXYRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXQfYpYUUN3ME2xNU4{QDl5IN88US=> NVnHeHUzW0GQR1XS
DEL NIjDUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3u4VmlEPTB;MUGuOFI1KM7:TR?= MV;TRW5ITVJ?
SW954 M1XySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn62TWM2OD1zMT60OlY5KM7:TR?= MWHTRW5ITVJ?
TK10 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPyS4x2UUN3ME2xNU42OjdzIN88US=> MoLwV2FPT0WU
SW756 NVvjSHhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjqTWM2OD1zMT61Nlk1KM7:TR?= M3uxS3NCVkeHUh?=
PC-3 NHXTVJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFzLkW3OlQh|ryP MoP4V2FPT0WU
ONS-76 MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVK3[|JNUUN3ME2xNU43OzZizszN Ml3lV2FPT0WU
A427 NHTvXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHKTWM2OD1zMT63NFk{KM7:TR?= MUHTRW5ITVJ?
MEG-01 Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHYNXNKSzVyPUGxMlc2ODlizszN Mo\vV2FPT0WU
BB30-HNC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\BdWlEPTB;MUGuO|k5OiEQvF2= NHHmfVJUSU6JRWK=
NCI-H1299 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGX1OWVKSzVyPUGxMlgxQTNizszN NGTMNFRUSU6JRWK=
GCT MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLBcWFKSzVyPUGxMlgzOjhizszN NYL6[o0{W0GQR1XS
D-247MG NX3o[ZpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDzXYZKSzVyPUGxMlk3PjNizszN NUfuXY9ZW0GQR1XS
CFPAC-1 M2nKUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFzLkm3PFIh|ryP MXvTRW5ITVJ?
EKVX NFrpWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DrNmlEPTB;MUKuNFMyOyEQvF2= M4rVUHNCVkeHUh?=
CAL-51 NGLYSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF{LkC3NVYh|ryP NYDSU2E3W0GQR1XS
BB49-HNC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHlXYJKSzVyPUGyMlEyPzdizszN M4\MNnNCVkeHUh?=
RPMI-7951 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYn1NZFZUUN3ME2xNk4yQDV2IN88US=> NHPjd4dUSU6JRWK=
RH-1 NHTPR|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDBO3FKSzVyPUGyMlIyQDRizszN NXrhWohFW0GQR1XS
BCPAP NHHEXFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz4V|RFUUN3ME2xNk41PzR7IN88US=> NYHYXZA3W0GQR1XS
GCIY NHjqfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF{LkWyNFkh|ryP NWTi[YNLW0GQR1XS
KNS-81-FD MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rnNmlEPTB;MUKuOVg3QSEQvF2= M2e4OnNCVkeHUh?=
KYSE-140 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF{Lki1PVUh|ryP NF3aWpVUSU6JRWK=
Ca-Ski NXLmOWJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u0[mlEPTB;MUKuPVA1OSEQvF2= MUTTRW5ITVJ?
TGBC1TKB MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYraTnA3UUN3ME2xNk46OTF3IN88US=> NVm2Wm5xW0GQR1XS
HCC1187 M4LNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M322NGlEPTB;MUOuNVkyOiEQvF2= NE\iRZdUSU6JRWK=
SJSA-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTF|LkKzNlch|ryP NHeyO5BUSU6JRWK=
CTV-1 NYPjcopJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3aTWM2OD1zMz6zOFUh|ryP NVPYRXZzW0GQR1XS
WM-115 NGPseHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfMVXVKSzVyPUGzMlY1QDNizszN MU\TRW5ITVJ?
CHP-212 M2DCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTF|Lkm3N|kh|ryP M32wVnNCVkeHUh?=
SCC-15 MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTF|Lkm3O|Uh|ryP MXLTRW5ITVJ?
BPH-1 NH3VNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3qxPGlEPTB;MUSuNVY3PCEQvF2= NHzySpZUSU6JRWK=
SW780 NGjYOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXNbIZ[UUN3ME2xOE42ODJ3IN88US=> MlLPV2FPT0WU
NCI-H2291 NYjzbWJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP5bHZKSzVyPUG0MlU5PzhizszN MlvUV2FPT0WU
JEG-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrQS3FPUUN3ME2xOE43OzJ4IN88US=> MUDTRW5ITVJ?
CAL-120 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3LTWM2OD1zND63NFI4KM7:TR?= NFXJS|NUSU6JRWK=
NCI-H23 NVO3OIhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzuSJNKSzVyPUG0Mlc6QTdizszN NXywXYpFW0GQR1XS
MS-1 NIP6c5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fpU2lEPTB;MUSuPVYyOSEQvF2= MXPTRW5ITVJ?
PC-14 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPRO2dFUUN3ME2xOE46PjV2IN88US=> M33rfnNCVkeHUh?=
D-283MED MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnPeolKSzVyPUG1MlAyOTFizszN M4KyVnNCVkeHUh?=
OE19 NF7jdplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu0[lVjUUN3ME2xOU4yPTRzIN88US=> Mm\wV2FPT0WU
CAS-1 M{GyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF3LkSxPFQh|ryP MVPTRW5ITVJ?
NCI-H727 M1TkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrZUYlKSzVyPUG1MlQzOjFizszN MkL0V2FPT0WU
SiHa NET6PYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkH4TWM2OD1zNT63OVk1KM7:TR?= NHTXblJUSU6JRWK=
BFTC-905 NYXEUWJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPSNXd6UUN3ME2xOU44Pjl2IN88US=> MlT6V2FPT0WU
MDA-MB-453 M2jUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWmyUVhqUUN3ME2xOk4yPjR{IN88US=> NYTNdlBtW0GQR1XS
HuP-T3 NYfjTYZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\4[4FmUUN3ME2xOk43Ozd|IN88US=> NWTwb|hkW0GQR1XS
SK-LU-1 NIXsdGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjqT3hKSzVyPUG2MlY6PTZizszN MmHLV2FPT0WU
Detroit562 NHjUeYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF4LkezNVgh|ryP NFvzPXlUSU6JRWK=
HCC1569 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonOTWM2OD1zNj64N|M4KM7:TR?= MVPTRW5ITVJ?
SK-MES-1 M{Lsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvPTWM2OD1zNj64OFE6KM7:TR?= NF7IfJdUSU6JRWK=
BB65-RCC M{HOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nzN2lEPTB;MUeuNFQ4QSEQvF2= NICwZXNUSU6JRWK=
LOXIMVI M3vNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Ll[GlEPTB;MUeuNFcxPyEQvF2= M1L1NHNCVkeHUh?=
SW1783 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PUdGlEPTB;MUeuNVI5KM7:TR?= NHXUe2ZUSU6JRWK=
NH-12 M4P1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXYZlFKSzVyPUG3MlM{ODNizszN M4e4Z3NCVkeHUh?=
UACC-257 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfZcJlSUUN3ME2xO{42PTF{IN88US=> MUHTRW5ITVJ?
KOSC-2 NYTjO2wyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHuTWM2OD1zNz62O|U4KM7:TR?= M3rXV3NCVkeHUh?=
KG-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3mTVJKSzVyPUG3MlY6OzdizszN MoHjV2FPT0WU
M059J MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF5LkewN{DPxE1? NIPuRYlUSU6JRWK=
MHH-NB-11 NWf4cVBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i0bGlEPTB;MUeuPVY4OyEQvF2= NXuyOJQzW0GQR1XS
EW-1 Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTF6LkGzPFIh|ryP M2T0cnNCVkeHUh?=
CAL-85-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2L3ZWlEPTB;MUiuNlM2PyEQvF2= MoLFV2FPT0WU
639-V NHyxfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTF6LkOzOVQh|ryP NUnXWoRXW0GQR1XS
C32 NIrQRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW0W2JRUUN3ME2xPE41PzJ5IN88US=> NYjK[ZBpW0GQR1XS
KM-H2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF6LkWyN|Ih|ryP MlL2V2FPT0WU
A253 M1v6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF6LkeyPFYh|ryP MUHTRW5ITVJ?
NCI-N87 M3\RRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF6LkmwNFgh|ryP NYTmcItlW0GQR1XS
8-MG-BA NYTnN4VlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LNVmlEPTB;MUmuNFY1PiEQvF2= MkS1V2FPT0WU
GI-ME-N NGPw[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWSwN5prUUN3ME2xPU4yPTR4IN88US=> NWrpclY5W0GQR1XS
8305C MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTF7LkKyPFYh|ryP M{\XRXNCVkeHUh?=
TE-8 M2DzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV32ZnF7UUN3ME2xPU4{ODJ2IN88US=> M{nOOHNCVkeHUh?=
KYSE-270 M4CyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzVeJJrUUN3ME2yNE4xOjF5IN88US=> NVe3TWRKW0GQR1XS
HL-60 NHfMWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\vb3g3UUN3ME2yNE4xQTRzIN88US=> MYnTRW5ITVJ?
Mo-T MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[xTWM2OD1{MD6xOlY2KM7:TR?= MV;TRW5ITVJ?
NCI-H1355 M4HGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrFV3RKSzVyPUKwMlM{PzRizszN NHmzR5FUSU6JRWK=
HT-1080 NEXGPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfCTVdKSzVyPUKwMlU1QTdizszN MonvV2FPT0WU
MIA-PaCa-2 M4i4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnlVFRKSzVyPUKwMlY5QDNizszN NEHRelJUSU6JRWK=
NCI-H441 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPiTWM2OD1{MD63N|c6KM7:TR?= MXHTRW5ITVJ?
LCLC-97TM1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4K0dmlEPTB;MkCuPFE{PCEQvF2= NUjrUWp2W0GQR1XS
HT-3 MmnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXOU5lKSzVyPUKxMlU3OzFizszN M2Ppe3NCVkeHUh?=
22RV1 NVjFS2hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXUfmxKSzVyPUKxMlU3QDVizszN Ml;LV2FPT0WU
LK-2 NYDoRoVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\0W2FKSzVyPUKxMlU6PTNizszN NFr3VmdUSU6JRWK=
CW-2 M3Lu[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjpfnBKSzVyPUKxMlYxPjlizszN M{m5d3NCVkeHUh?=
KYSE-510 NUPFU442T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nUN2lEPTB;MkGuOlA6PSEQvF2= NUexXHFFW0GQR1XS
CGTH-W-1 NUPoRppnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnsTWM2OD1{MT63NVY3KM7:TR?= MkfBV2FPT0WU
NCI-H661 NGXR[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1SwW2lEPTB;MkKuNFM1KM7:TR?= Mk\JV2FPT0WU
KU-19-19 NWnzSYg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXmZ3Z5UUN3ME2yNk4yPjl5IN88US=> MoK1V2FPT0WU
NCI-H2122 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3G0PWlEPTB;MkKuNlQ{OiEQvF2= MU\TRW5ITVJ?
NCI-H526 M4e1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS4cZVHUUN3ME2yNk4{QDl3IN88US=> MlnoV2FPT0WU
NCI-H1650 M{fOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPqW211UUN3ME2yNk44PjRizszN NGrHdWFUSU6JRWK=
AM-38 NXjH[IRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILTN5ZKSzVyPUKyMlg3QDlizszN MnzCV2FPT0WU
NCI-H2405 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUS1Z5hDUUN3ME2yN{4zPTN|IN88US=> M{jMS3NCVkeHUh?=
M14 M2HwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH2WGZKSzVyPUKzMlQxQDhizszN MoHoV2FPT0WU
ES4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEGxbVVKSzVyPUKzMlQzOzJizszN MWfTRW5ITVJ?
DJM-1 NYjYXpNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTjVW9vUUN3ME2yN{42OjN2IN88US=> MWHTRW5ITVJ?
S-117 NUey[4VnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrtbm9KSzVyPUKzMlc3PTFizszN M{LmSnNCVkeHUh?=
MZ2-MEL M1i2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\nTWM2OD1{Mz63O|U6KM7:TR?= NET4WHdUSU6JRWK=
SK-MEL-2 NUK5OJJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJ|LkixN|Mh|ryP MkDCV2FPT0WU
HCC1806 M4e5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS0UW9KSzVyPUKzMlg4ODlizszN M1rKOXNCVkeHUh?=
NMC-G1 NELHR45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn4TWM2OD1{ND6yNlI3KM7:TR?= Mlm2V2FPT0WU
DK-MG NGnFSoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:wV3RmUUN3ME2yOE4zQTRizszN Mmi0V2FPT0WU
SK-N-FI MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfQbI5KSzVyPUK0MlM{ODJizszN Mm\ZV2FPT0WU
KINGS-1 Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XCcWlEPTB;MkSuOFg4PCEQvF2= M3L3N3NCVkeHUh?=
HCC2998 M2XIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S0TWlEPTB;MkSuOFg5PSEQvF2= NUPmfnlbW0GQR1XS
ALL-PO NYPzcZRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHvfpFKSzVyPUK0MlYyQSEQvF2= MkXnV2FPT0WU
MPP-89 M1LIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\LNWlEPTB;MkWuNFQ2QCEQvF2= M4rwPXNCVkeHUh?=
NCI-H2342 NYeyWVczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r0bGlEPTB;MkWuNVk2OyEQvF2= M4fWfHNCVkeHUh?=
TE-1 MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJ3LkO1OlMh|ryP MYDTRW5ITVJ?
RH-18 M125b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJ3LkW5NVgh|ryP NX7HT2dNW0GQR1XS
HT-1376 M3jUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHpTWM2OD1{NT62OFY2KM7:TR?= NVq0eJU{W0GQR1XS
U-2-OS NWDqflBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPsTXJTUUN3ME2yOU43QDh6IN88US=> Mnq4V2FPT0WU
BT-549 NFfNNmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmexTWM2OD1{NT65NFEyKM7:TR?= M1XyXHNCVkeHUh?=
NCI-H1755 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL4TWM2OD1{NT65PVQ2KM7:TR?= MlvaV2FPT0WU
EW-13 NUjtfJhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzGTWM2OD1{Nj6wNlc1KM7:TR?= MonQV2FPT0WU
NB13 M2Lq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfHbmdKSzVyPUK2MlA6PDlizszN MYDTRW5ITVJ?
NUGC-3 M3;3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfBfoR6UUN3ME2yOk4zOTB|IN88US=> M3HhcHNCVkeHUh?=
GMS-10 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofvTWM2OD1{Nj6yN|U{KM7:TR?= NV\XZ|JGW0GQR1XS
CHP-134 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3kU2VKSzVyPUK2MlM5PjdizszN M1vn[nNCVkeHUh?=
SW962 NWftSGhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJ4LkWwNlEh|ryP M1\3RnNCVkeHUh?=
SNU-449 M{jvO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rXXWlEPTB;MkeuNFgxOyEQvF2= M2\DSXNCVkeHUh?=
HuP-T4 M1m4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HZO2lEPTB;MkeuNFg4QSEQvF2= M2HxOXNCVkeHUh?=
SW948 Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\CTWM2OD1{Nz6xN|Q1KM7:TR?= MkH2V2FPT0WU
NCI-H226 MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf6doprUUN3ME2yO{41PTd6IN88US=> MV3TRW5ITVJ?
SK-PN-DW NIW3VplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PDfWlEPTB;MkeuOlAyOiEQvF2= NFn2V3dUSU6JRWK=
GI-1 M4S2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfzTWM2OD1{Nz63NlEh|ryP NVLDZ5AzW0GQR1XS
CAL-12T MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfDTWM2OD1{OD6xNVEzKM7:TR?= NIXpVIRUSU6JRWK=
YAPC NUHSU3JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLPTWM2OD1{OD6yOVY1KM7:TR?= MoXoV2FPT0WU
SNU-C2B MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDzcodEUUN3ME2yPE4zQTZ2IN88US=> NGf6TmFUSU6JRWK=
RCC10RGB MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\oSXFKSzVyPUK4MlU1OTdizszN M{DRbXNCVkeHUh?=
ES7 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJ7LkG0OlUh|ryP M3vzRnNCVkeHUh?=
PANC-03-27 NXzsfVBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXv2[GZLUUN3ME2yPU41PDRizszN NHTPbGRUSU6JRWK=
ES6 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW0TWM2OD1{OT64NVU4KM7:TR?= NFTmelFUSU6JRWK=
HT-1197 MoL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;nXo5KSzVyPUOwMlA2QThizszN MV3TRW5ITVJ?
ZR-75-30 MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnmTWM2OD1|MD6yN|g{KM7:TR?= M2Wzb3NCVkeHUh?=
DB NYjWbGV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTNyLkS5OFIh|ryP M1vXRXNCVkeHUh?=
OCI-AML2 MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\xXppKSzVyPUOxMlA3QSEQvF2= M1\yOnNCVkeHUh?=
NCI-H2170 NEm1WGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7iRnFSUUN3ME2zNU45PTF4IN88US=> NYfm[FN{W0GQR1XS
IST-MES1 NFXH[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LLfGlEPTB;M{KuNlg6PyEQvF2= M2fUZ3NCVkeHUh?=
769-P MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;jbllTUUN3ME2zNk4{PjRzIN88US=> NXrYdJFVW0GQR1XS
COR-L23 M3vUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFT5RnVKSzVyPUOyMlkxPzNizszN MmHGV2FPT0WU
SW626 NV24eoxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYSzOIdJUUN3ME2zN{4yPzd4IN88US=> M2fYW3NCVkeHUh?=
LU-139 MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;iOXdKSzVyPUOzMlY3ODVizszN NEO2O2xUSU6JRWK=
HT-144 NFjQe2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTN|Lki2N{DPxE1? NF[0PINUSU6JRWK=
CaR-1 NUKwWVBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXaWFVKSzVyPUOzMlk5OjJizszN NYPzSplsW0GQR1XS
OE33 NXOzPJpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTN2LkK4OVUh|ryP M3vOOnNCVkeHUh?=
COLO-800 NVfmbIZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTN2LkO2OFch|ryP M2e4S3NCVkeHUh?=
NB14 M4DrcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTN2LkS2PFQh|ryP MWDTRW5ITVJ?
KURAMOCHI NI\FZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nTNmlEPTB;M{[uNVE6QCEQvF2= MXvTRW5ITVJ?
SW48 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLBflg6UUN3ME2zOk4zPDd2IN88US=> M2jXWnNCVkeHUh?=
Daoy MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G0fmlEPTB;M{[uOlU{QCEQvF2= NIXETHFUSU6JRWK=
TGBC24TKB MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjMOpJSUUN3ME2zOk43PyEQvF2= MY\TRW5ITVJ?
DU-4475 M4jzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTN4LkmwN|Mh|ryP MlHkV2FPT0WU
SW1417 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTheoo1UUN3ME2zPE4xPTV{IN88US=> MXXTRW5ITVJ?
EFO-21 Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXoTWM2OD1|OD65N|Q6KM7:TR?= NXjq[JdXW0GQR1XS
MG-63 M361fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWW5fm9VUUN3ME2zPU4{PDJ2IN88US=> NV;tdYtCW0GQR1XS
LC-2-ad MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\lTWM2OD1|OT61OVEzKM7:TR?= MV\TRW5ITVJ?
NOMO-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jZPGlEPTB;M{muPFI4PCEQvF2= NF63THlUSU6JRWK=
COLO-741 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTRyLkGzNFQh|ryP M{XPWXNCVkeHUh?=
BxPC-3 NGnVRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTRyLkW2PFYh|ryP NWHVfY9bW0GQR1XS
HSC-2 MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTRyLkmxNVMh|ryP NXP0V45VW0GQR1XS
UMC-11 MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEm3bItKSzVyPUSxMlI3OyEQvF2= NUTCb243W0GQR1XS
HCC1937 MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEmwbJpKSzVyPUSyMlc5PDNizszN M2LTW3NCVkeHUh?=
Calu-6 Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHmTWM2OD12Mz6yN|gzKM7:TR?= NIftb3RUSU6JRWK=
NCI-H1573 NVfsSohtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTR|LkO0O|ch|ryP NXrLVYFLW0GQR1XS
SK-N-AS NH;SdlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf2RW1KSzVyPUSzMlYxOTlizszN MWLTRW5ITVJ?
PSN1 M2S3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTR3LkK1OFgh|ryP NHrENWxUSU6JRWK=
TE-11 M2PoNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoezTWM2OD12NT60PFQzKM7:TR?= MmLYV2FPT0WU
NCI-H1155 M4e3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPNfVRKSzVyPUS1Mlg6PjdizszN NXXS[XNGW0GQR1XS
KM12 NFS2e3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTR3LkmwO|Yh|ryP NUXINVhZW0GQR1XS
RO82-W-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjBdJRKSzVyPUS2Mlk5OjJizszN M3npU3NCVkeHUh?=
SW1573 M2LwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPHTWM2OD12Nz6zO|M3KM7:TR?= M1rLZ3NCVkeHUh?=
CAKI-1 NFvLbXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1mzZWlEPTB;NEiuNlg1PSEQvF2= MWPTRW5ITVJ?
U-118-MG NYrqNnBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPrTWM2OD12OD6zO|AzKM7:TR?= NULH[nc5W0GQR1XS
KYSE-520 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojRTWM2OD12OD60NFE3KM7:TR?= Mlq1V2FPT0WU
HT55 NFXYTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjaPWRKSzVyPUS5MlE1PzRizszN Mnm5V2FPT0WU
ChaGo-K-1 NIm4SVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTR7LkS3PVMh|ryP MWXTRW5ITVJ?
IA-LM MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHyTWM2OD13ND62N|IzKM7:TR?= MoDSV2FPT0WU
UACC-62 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TXU2lEPTB;NUWuNVA1PiEQvF2= NHnBNIxUSU6JRWK=
MKN7 MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHvTWM2OD13Nj6wNlg2KM7:TR?= MWDTRW5ITVJ?
HPAF-II MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zCfGlEPTB;NU[uOFA4OyEQvF2= NUfTUFFLW0GQR1XS
NTERA-S-cl-D1 NXz1Z5BiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXKzUW9iUUN3ME21O{44PzhizszN NV3Rdo9GW0GQR1XS
FTC-133 NYPxSGdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vvS2lEPTB;NUiuNFk3QSEQvF2= MWLTRW5ITVJ?
MHH-ES-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLGO5o6UUN3ME21PE41QDF2IN88US=> MnjZV2FPT0WU
JVM-2 M2Pyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jK[2lEPTB;NUiuPVUxPiEQvF2= NVzrWXNrW0GQR1XS
TCCSUP NIjOWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELsUZVKSzVyPUW5MlUzPzlizszN NWqwWZo3W0GQR1XS
COLO-824 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[3TWM2OD14MD6wO|E6KM7:TR?= NG\YTI5USU6JRWK=
647-V NGrweJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTZyLkGzOFch|ryP NF3EdY5USU6JRWK=
HD-MY-Z NYKzeoFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHruW2pKSzVyPU[wMlUzQTRizszN NWDzXohXW0GQR1XS
LS-411N MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\lPHRFUUN3ME22NU4{QTB|IN88US=> NX;OSpRFW0GQR1XS
NCI-H596 NUHTdVFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrCe4xKSzVyPU[yMlc1QTZizszN MYXTRW5ITVJ?
C-33-A M1fBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTZ2LkC5OVch|ryP NHPnT3JUSU6JRWK=
BHY NIfjd2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3OOXRSUUN3ME22OE4yOjR3IN88US=> MofuV2FPT0WU
KGN MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\RSGlEPTB;NkSuOVUyPCEQvF2= MlPmV2FPT0WU
NCI-H1092 M{H4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnhUHNKSzVyPU[1MlAxQTVizszN NFfyb5pUSU6JRWK=
MZ1-PC M1;OWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;VTWM2OD14NT61OlQ6KM7:TR?= M4HibXNCVkeHUh?=
LB831-BLC MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTZ3Lki0PFEh|ryP MV;TRW5ITVJ?
SW620 NVr1XnZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHEcmdKSzVyPU[2MlIxOzlizszN NU\2Nm9sW0GQR1XS
HuO-3N1 NGn2NYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFm1ZZJKSzVyPU[4MlMzOzhizszN Mn\tV2FPT0WU
SK-HEP-1 NFj5XI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;lTWM2OD14OT65OFg3KM7:TR?= NY\Lb5RCW0GQR1XS
LCLC-103H MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTifmFWUUN3ME23NE43PzB3IN88US=> Mn\5V2FPT0WU
KYSE-70 M2C4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnhPGhKSzVyPUewMlc5OzVizszN NIHt[GFUSU6JRWK=
Mewo NU\6V3BKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknuTWM2OD15MT61NFUh|ryP M4nqcnNCVkeHUh?=
COLO-668 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHUN3NNUUN3ME23NU45PDVzIN88US=> NEjON3FUSU6JRWK=
NCI-H522 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3q3VmlEPTB;N{KuN|QyOyEQvF2= MoHjV2FPT0WU
NCI-H1437 M{\SS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmP2TWM2OD15ND60NFQ5KM7:TR?= NYrpO2g2W0GQR1XS
U-266 MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHOTWM2OD15NT60OVE3KM7:TR?= NUi0SmdVW0GQR1XS
MC116 Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7JTWM2OD15NT61O|A5KM7:TR?= MlXrV2FPT0WU
PANC-10-05 MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTd5LkSyOFMh|ryP NX3jNVFmW0GQR1XS
KYSE-180 M17ROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG4TWM2OD15Nz61OFU1KM7:TR?= M4HRfXNCVkeHUh?=
JAR MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz2TWM2OD15OT6wOVQ3KM7:TR?= MmWwV2FPT0WU
CAL-62 NVHGRWRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTnTWM2OD16MD6wPVUh|ryP NXL1N29xW0GQR1XS
A3-KAW NVPKR5JYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnrTWM2OD16MD6yNVU1KM7:TR?= MnzUV2FPT0WU
PANC-08-13 NXvnco9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PlT2lEPTB;OEGuNVc3QCEQvF2= MYXTRW5ITVJ?
HSC-3 NEPsUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3CTWM2OD16Mz6zNFcyKM7:TR?= NVTwXlF5W0GQR1XS
HTC-C3 MlnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXIUnBKSzVyPUizMlQ4ODJizszN MlmzV2FPT0WU
KY821 NVjXO5hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{GwVmlEPTB;OESuNFg6OiEQvF2= MnrhV2FPT0WU
DoTc2-4510 NI\WOHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O1fWlEPTB;OESuNlE5PSEQvF2= MkfEV2FPT0WU
NCI-H1581 M3HV[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHZbJh2UUN3ME24OU41PjRzIN88US=> MVHTRW5ITVJ?
KARPAS-299 NYj6T2V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPqTWM2OD16Nj6xPVc4KM7:TR?= NFS5WVBUSU6JRWK=
IST-MEL1 M3fST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGC0O5dKSzVyPUi2Mlg5PzJizszN NXj5OXlSW0GQR1XS
KP-N-YS MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7jUG84UUN3ME24PU46ODJ6IN88US=> M3HvUHNCVkeHUh?=
KYSE-410 NYDLXok{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i2U2lEPTB;OUGuOFA1OiEQvF2= MYnTRW5ITVJ?
TE-10 NVLzWG9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHyWGVKSzVyPUmxMlU3OTFizszN NFvYVo1USU6JRWK=
SK-MEL-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXtV3RKSzVyPUmyMlkyODZizszN NUm1OGNWW0GQR1XS
COLO-792 MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7ofZlVUUN3ME25OU4zPTZ2IN88US=> NE\Tc4lUSU6JRWK=
SCH NFzoNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTl4LkO4O|ch|ryP NF;wRnZUSU6JRWK=
NCI-H1792 NXWyW4VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvpTWM2OD17Nj64PVkzKM7:TR?= NUHkSoFEW0GQR1XS
NCI-H2029 NInKbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XxPWlEPTB;OU[uPVU3PiEQvF2= MkTXV2FPT0WU
SW684 M4K4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoToTWM2OD17OD62OlU1KM7:TR?= MlnNV2FPT0WU
NCI-H209 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFyMD6xNlEh|ryP MUfTRW5ITVJ?
HLE M3LiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfOUpZKSzVyPUGwOU4zQDJizszN NXTGcFZzW0GQR1XS
GOTO NYT2ZXc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3GycGlEPTB;MUC3Mlc4PyEQvF2= NVjLcFNwW0GQR1XS
NCI-H1793 NW\sSo05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFyOT6yPEDPxE1? M17wUHNCVkeHUh?=
D-392MG NYjxTWhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnewTWM2OD1zMUeuN|k5KM7:TR?= MUjTRW5ITVJ?
SW1990 NIP4S5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF{MD65OVEh|ryP M4niTXNCVkeHUh?=
ML-2 NULxPVNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF{MT62O|Yh|ryP Mn;mV2FPT0WU
NCI-H2452 NYTIU4ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH3eHBKSzVyPUGyNk4zOSEQvF2= NEDYcJlUSU6JRWK=
SK-MEL-30 M4[0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2q2VGlEPTB;MUKzMlI1PCEQvF2= M2rMSXNCVkeHUh?=
SN12C MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXD[FRKSzVyPUGyOE4yPzZizszN MWDTRW5ITVJ?
NCI-H1770 M1j6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF{NT61NVQh|ryP NEnBOItUSU6JRWK=
SF268 NFXENnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\DTWM2OD1zMk[uNVU5KM7:TR?= NXnmbnFTW0GQR1XS
BALL-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXpTWM2OD1zMk[uNlMh|ryP MojlV2FPT0WU
COLO-679 NILGPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTF{Nj63OVMh|ryP MnmzV2FPT0WU
A2780 NVrmbZZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L2cGlEPTB;MUK4Mlk5QCEQvF2= NXH3SY9sW0GQR1XS
NCI-H1651 M{DCU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVe2UmM{UUN3ME2xN|EvOjR|IN88US=> MoTPV2FPT0WU
NCI-H2087 M1:zbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rOZWlEPTB;MUOxMlQ5OyEQvF2= NHe1c|RUSU6JRWK=
U-87-MG NYTaR3lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF|Mz62NFQh|ryP MnL5V2FPT0WU
LB2518-MEL NFjFZ3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLtN2djUUN3ME2xN|UvQTl|IN88US=> NGjMfXhUSU6JRWK=
HCT-116 NFvDem1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXG2[HlRUUN3ME2xN|cvOjF5IN88US=> Mn;RV2FPT0WU
Ca9-22 NWi2VlFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLwTWM2OD1zM{muPFM{KM7:TR?= NF\vb2tUSU6JRWK=
COR-L88 M4PTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDBTWM2OD1zNEKuNVQh|ryP M4LpdHNCVkeHUh?=
CP50-MEL-B MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\hTWM2OD1zNESuOVAyKM7:TR?= MnHRV2FPT0WU
OVCAR-8 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnkUFJKSzVyPUG0OU43OzZizszN M3TOOnNCVkeHUh?=
SK-MEL-3 NWPKfmlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XzdmlEPTB;MUS3Mlg4QCEQvF2= MVrTRW5ITVJ?
GT3TKB NGPGb41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[zWnRKSzVyPUG0PU46OjhizszN NXrWeoF{W0GQR1XS
KYSE-450 NYjVO5JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[0TWM2OD1zNUGuOVM6KM7:TR?= MULTRW5ITVJ?
CAPAN-1 M1joVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rQU2lEPTB;MUWzMlA3PCEQvF2= NXfFOYFFW0GQR1XS
BEN NIXIfWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF3Mz65Nlgh|ryP Mn;ZV2FPT0WU
NCI-H1304 M4n1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoO3TWM2OD1zNUSuOlk1KM7:TR?= NHrR[VJUSU6JRWK=
KU812 Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r4WmlEPTB;MUW4MlY4PCEQvF2= M3XPR3NCVkeHUh?=
Capan-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTF4MD61OVMh|ryP MUXTRW5ITVJ?
A673 M2LvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\hcFh4UUN3ME2xOlEvPzB3IN88US=> M2\NUHNCVkeHUh?=
SAS M4CzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTF4Mj62O|gh|ryP NYjUPXBKW0GQR1XS
NY NYnwPFN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELNXFBKSzVyPUG2OU4{OTRizszN NUPPOZVZW0GQR1XS
HCE-4 M{PqNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HvcGlEPTB;MU[2Mlg1PSEQvF2= MXfTRW5ITVJ?
MDA-MB-231 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4i0SmlEPTB;MUe3MlUxOyEQvF2= MWHTRW5ITVJ?
no-10 NFjoNWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHYclFMUUN3ME2xO|gvOTN2IN88US=> MlvEV2FPT0WU
MZ7-mel M1:1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF5OD60Olch|ryP MnG0V2FPT0WU
NCI-H82 MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF6MD6xOlUh|ryP MnzjV2FPT0WU
CAL-72 MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHpemdWUUN3ME2xPFUvODV2IN88US=> MUHTRW5ITVJ?
NCI-SNU-5 M{H5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle5TWM2OD1zOE[uPFQh|ryP M1\jR3NCVkeHUh?=
OVCAR-4 MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXqTWM2OD1zOEiuN|M{KM7:TR?= NFnUPJhUSU6JRWK=
SCC-9 NIfY[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTF7MTFOwG0> MkfSV2FPT0WU
KYSE-150 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3OzRmlEPTB;MUmxMlg5QCEQvF2= NEHXPXJUSU6JRWK=
HT-29 NUjKeXlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTFTWM2OD1{MEGuNlEzKM7:TR?= NUH2S4puW0GQR1XS
COLO-678 MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJyMT60OUDPxE1? MYXTRW5ITVJ?
NCI-H650 MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C0N2lEPTB;MkCyMlExOyEQvF2= M{LLXnNCVkeHUh?=
HuCCT1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVmwTpk3UUN3ME2yNFQvOjB6IN88US=> MmOyV2FPT0WU
SW1116 NX3Cc291T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDlfWJKSzVyPUKwO{4xPzdizszN NYnrS2ROW0GQR1XS
DBTRG-05MG MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3rWJBUUUN3ME2yNFcvQTB7IN88US=> NEDEVFRUSU6JRWK=
SW982 NUHrcWVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXzclZtUUN3ME2yNFcvQTR6IN88US=> MlryV2FPT0WU
RCM-1 M4\jVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK5SW5KSzVyPUKxOE44PjJizszN M{DjbHNCVkeHUh?=
COLO-320-HSR M17yTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXZVlBKSzVyPUKxOk4yOjVizszN NUGxOFJnW0GQR1XS
KNS-42 NUDGWXd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoT4TWM2OD1{MU[uOVc1KM7:TR?= NWXUZ4xzW0GQR1XS
C2BBe1 NHrNXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJ|MT65NFUh|ryP MX7TRW5ITVJ?
CCRF-CEM M{faW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3hTWM2OD1{NEOuO|k2KM7:TR?= MWXTRW5ITVJ?
SH-4 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJ2Nj6wPUDPxE1? MWjTRW5ITVJ?
LS-1034 M2DXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUG2dZVxUUN3ME2yOFYvOjZ4IN88US=> NWq5Z|hYW0GQR1XS
NCI-H2347 NXz5elczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJ2Nz63NVMh|ryP M1;mZ3NCVkeHUh?=
RPMI-8866 M13GdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zDT2lEPTB;MkS5MlI4KM7:TR?= NX\oUZlkW0GQR1XS
GAK MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[0TWM2OD1{NUOuNFAzKM7:TR?= MYjTRW5ITVJ?
NB6 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJ5MD6xJO69VQ>? NYjtdoM1W0GQR1XS
COLO-680N M{S4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJ5Mj61Nlch|ryP NVfmXJQ1W0GQR1XS
RERF-LC-MS MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXNTWM2OD1{N{[uNFA4KM7:TR?= MlnoV2FPT0WU
TGBC11TKB NYq2SlY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjKd5hKSzVyPUK3PE4yPzhizszN MW\TRW5ITVJ?
C8166 M{X5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\LdlhvUUN3ME2yO|gvPTB4IN88US=> NHHsO5NUSU6JRWK=
HDLM-2 NHLV[XdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\FfWxMUUN3ME2yPVQvPDB7IN88US=> NEnPeVFUSU6JRWK=
IGR-1 NEfYdnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLRfZlGUUN3ME2yPVUvPjV7IN88US=> NGLHfWNUSU6JRWK=
FADU M4DBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJ7Nz61NUDPxE1? M1zjO3NCVkeHUh?=
L-428 NWLlXZBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M16zW2lEPTB;Mkm3MlYyPiEQvF2= NGm2dIlUSU6JRWK=
LU-65 MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXITWM2OD1|MESuN|Ih|ryP NXXPTGxwW0GQR1XS
HEL NV;MSml1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\UTWM2OD1|MEmuPVg{KM7:TR?= MVfTRW5ITVJ?
NCI-H810 MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33tUWlEPTB;M{GwMlU4KM7:TR?= MkLkV2FPT0WU
C3A M1Ludmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjWNGNKSzVyPUOxNU45ODJizszN M{DxdHNCVkeHUh?=
NCI-H630 M3HDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnMTWM2OD1|M{KuNlk1KM7:TR?= M4PXbnNCVkeHUh?=
KP-N-YN M3ntfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn31TWM2OD1|NEGuNVI{KM7:TR?= M3TpbXNCVkeHUh?=
MOLT-13 M4nzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF2zbpRKSzVyPUO0Nk4{OjZizszN NF\x[INUSU6JRWK=
NCI-H1993 MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXC[XQ1UUN3ME2zOFIvOzZ3IN88US=> M2LGfXNCVkeHUh?=
BE-13 M{\Femdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\lTWM2OD1|NESuNVY4KM7:TR?= MWjTRW5ITVJ?
IST-SL1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnvTWM2OD1|NEeuOFAyKM7:TR?= MUjTRW5ITVJ?
TE-9 MojrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnpPW53UUN3ME2zOlMvPTh7IN88US=> MUHTRW5ITVJ?
LU-135 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NED4dphKSzVyPUO2O{4xOzVizszN MYfTRW5ITVJ?
T84 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrrTWM2OD1|N{SuO|EzKM7:TR?= NEKySHFUSU6JRWK=
K-562 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkP5TWM2OD1|OEOuN|Yh|ryP NIDZRZFUSU6JRWK=
SBC-5 MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vK[2lEPTB;M{i2Mlk5PSEQvF2= MlLiV2FPT0WU
NB17 NWT0do5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3za[2lEPTB;M{myMlU6PiEQvF2= Ml[zV2FPT0WU
NCI-H2052 M4nqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1KyOGlEPTB;M{m4MlQ4OiEQvF2= NHm5V3VUSU6JRWK=
HCC38 MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnQTWM2OD12MEGuOVk{KM7:TR?= MXPTRW5ITVJ?
NCI-H69 M3T0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTGXpZrUUN3ME20OFEvODh|IN88US=> M374Z3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

体内研究 MK-2206和这些细胞毒素药剂联用作用于NCI-H292移植瘤,MK-2206显示出非常有效的抗癌活性。卵巢癌A2780移植瘤中,按动物体重,每千克处理240mg MK-2206,则可抑制70%以上的Akt1/2在苏氨酸308位点和丝氨酸473位点的磷酸化,导致肿瘤生长抑制率达到60%。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[3]

+ 展开

Akt激酶实验:

通过得到的GSK 生物素肽段基质测定Akt激酶。使用含镧系金属螯合物偶联单抗的均相时间分辨荧光(HTRF)测定肽段磷酸化程度,这种单抗专门作用于与链霉亲和素——藻蓝素(SA-APC)载体相结合的磷酸化作用,SA-APC载体可以结合到肽段的部分生物素上。当镧系金属螯合物与藻蓝素相接触时,无辐射的能量从镧系金属螯合物传递给藻蓝素,然后藻蓝素发射波值为655纳米的光线。工作液:100X 蛋白酶抑制剂混合物(PIC):1mg/ml苯甲脒,0.5 mg/ml 抑肽素, 0.5 mg/ml亮抑肽酶, 0.5 mg/ml 抑肽酶。10X实验 buffer: 500 mM HEPES(pH 为7.5), 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-甘油磷酸。抑制 buffer:50 mM HEPES(pH为7.3), 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM 标记的单抗, 0.0067mg/ml SA-APC。ATP/MgCl2工作液: 1X 实验buffer, 1 mM DTT, 1X PIC, 5% 甘油, 激活的Akt。肽段工作液:1X实验buffer, 1 mM DTT, 1X PIC, 5% 甘油 2 TM GSK生物素肽段。工作液加到合适的孔中,然后加入总负荷为16的 ATP/MgCl2,反应开始。含MK-2206的实验组和对照组加入总负荷为10的肽段工作液。然后加入总负荷为13的酶液,混匀。反应进行50分钟,然后加入总负荷为60的均相时间分辨荧光抑制buffer停止反应。阻断的反应在室温下温育30分钟以上,然后使用仪器读数。
细胞实验:

[2]

+ 展开
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6,和NCI-H460细胞
  • Concentrations: 0, 0.3, 1,和3 μM
  • Incubation Time: 72或96小时
  • Method:

    MK-2206溶解在DMSO中,在实验使用前用培养基稀释。细胞按2~3×103密度接种在96孔板上,温育24小时。MK-2206 (分为0, 0.3, 1,和3 μmol四组)处理细胞,72或者96小时后,测定细胞增殖情况。


    (Only for Reference)
动物实验:

[2]

+ 展开
  • Animal Models: 携带SK-OV-3, NCI-H292, HCC70, PC-3,和NCI-H460模型的雄性CD1裸鼠
  • Formulation: 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
15% Captisol
17 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 480.39
化学式

C25H21N5O.2HCl

CAS号 1032350-13-2
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01306045 Recruiting Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Carcinoma, Thymic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 21, 2011 Phase 2
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Active, not recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • 回答:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • 问题 2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • 回答:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

相关Akt产品

Tags: 购买MK-2206 2HCl | MK-2206 2HCl供应商 | 采购MK-2206 2HCl | MK-2206 2HCl价格 | MK-2206 2HCl生产 | 订购MK-2206 2HCl | MK-2206 2HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID